MedicalResearch.com Interview with:
[caption id="attachment_53705" align="alignleft" width="136"]
Prof. McMurray[/caption]
John J. V. McMurray, MD FRCP FESC FACC FAHA FRSE FMedSci
British Heart Foundation Cardiovascular Research Centre
University of Glasgow
Glasgow, United Kingdom
[caption id="attachment_53709" align="alignleft" width="200"]
Dr. Docherty[/caption]
Kieran F Docherty
DAPA-HF investigator
British Heart Foundation Cardiovascular Research Centre,
University of Glasgow
MedicalResearch.com: What is the background for this study?
Response: DAPA-HF was a double-blind randomized controlled trial comparing dapagliflozin 10 mg once daily with placebo in 4744 patients with heart failure and reduced ejection fraction (HFrEF).
The primary outcome was a composite of time to occurrence of a worsening heart failure event (principally heart failure hospitalization) or cardiovascular death, whichever came first.
Dapagliflozin reduced the primary outcome by 26% and reduced the risk of each of heart failure hospitalization and cardiovascular death individually, as well as overall mortality. Patient symptoms were also improved.
The aim of the present report was to examine the effect of dapagliflozin separately in patients with and without type 2 diabetes at baseline (45/55% split in the trial). The reason for this was that dapagliflozin was originally introduced as a glucose-lowering medication for the treatment of type 2 diabetes. We find that dapagliflozin was equally beneficial in patients with and without diabetes and was as well tolerated in patients without diabetes as in those with diabetes. More remarkably, among the patients without diabetes, dapagliflozin was as effective in participants with a completely normal glycated haemoglobin (HbA1c) as in those with prediabetes. In patients with a normal HbA1c, dapagliflozin did not lead to any reduction in HbA1c, but did improve clinical outcomes.
Dr. Hosie[/caption]
Margaret J. Hosie BVM&S, MRCVS, BSc. PhD.
Professor of Comparative Virology
MRC-University of Glasgow Centre for Virus Research
United Kingdom
MedicalResearch.com: What is the background for this study?
Response: SARS-CoV-2 is a new coronavirus of animal origin that recently jumped to humans and has spread rapidly across the world. It is likely that SARS-CoV-2 will establish as an endemic virus of humans, which has the potential to be transmitted to animals that live in close proximity to humans. There have been sporadic reports of infections in pet cats in households with COVID-19 patients, which demonstrates that cats are susceptible to SARS-CoV-2 infection and could act as virus reservoirs.